VIZ Plain Royal Blue Adjustable Baseball Cap

Product Information

Reported allergic reactions and side effects to COVID-19 vaccines are published weekly in our Reported side effects following COVID-19 vaccination report. Vaccine review, approval and monitoring The monovalent Omicron XBB 1.5 subvariant multi-dose vial has a royal blue plastic cap and coral blue label.

The Moderna Spikevax ® COVID-19 vaccine is approved for primary vaccination in people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months have not yet been established. This vaccine is also approved as a booster for people 12 years of age and older. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence. The bivalent Original/Omicron BA.1 0.1 mg/mL multi-dose vial has a royal blue plastic cap and green label.A different vaccine may be offered for your second dose. For example, you may have received Pfizer-BioNTech Comirnaty ® as your first dose and be offered Moderna Spikevax ® as your second. This is known as a mixed vaccine series. Find detailed technical information such as the product monograph and the regulatory decision summary: A severe allergic (anaphylaxis) reaction is also rare. Signs and symptoms of anaphylaxis may include: The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty ® or Moderna Spikevax ®) should be offered for your second dose.

The mRNA sequence from Moderna Spikevax ® COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.1 variant.

Dose volume depends on which series of the vaccine is being administered. The dose for people 12 years of age and older (100 micrograms) is:

The safety and effectiveness of the Moderna Spikevax® Monovalent COVID-19 vaccine (Omicron XBB 1.5) is based on studies of Spikevax® (Original, Original/Omicron BA.1 & XBB.1.5). Dosage Primary seriesThe bivalent Original/Omicron BA.4/5 0.1 mg/mL multi-dose vial has a royal blue plastic cap and grey label. The Moderna Spikevax®Monovalent COVID-19 vaccine(Omicron XBB.1.5 subvariant) is approved for people who are 6 months of age and older. It may be given to people who have been previously vaccinated or who have not been previously vaccinated. Its safety and effectiveness in people younger than 6 months has not yet been established. Effectiveness months to 4 years (25 micrograms at least 6 months after their previous dose). If the child has not been previously vaccinated, Spikevax XBB.1.5 should be administered a 2-dose regimen.